HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: NAD Decisions, Warning Letters, EC Law Struck, “Natural” Claims Suit

This article was originally published in The Tan Sheet

Executive Summary

Pharmavite discontinues ads; NAD looks at supplement concussion claims; FDA warns product requires NDI; Spinal Touch Formulas are unapproved new drugs – FDA; Weight-loss products unapproved, misbranded; Oklahoma law restricting contraception knocked down; and Hammer Nutrition sued over “natural” claims

You may also be interested in...



Claims Emerge To Join “Natural” As Class Action Fodder

Claims a product is “natural,” health and prevention claims, “whole grain” and “made with” claims, all can put a firm at risk for a lawsuit, the Center for Science in the Public Interest warns. After climbing for five years in a row, class action lawsuits brought against food products dipped in 2013, but the decline may be short-lived.

Spiked “Supplements” For Diabetes, Pain On The Rise

FDA is seeing supplements spiked with Rx ingredients indicated for pain management and diabetes treatment, and needs industry help identifying violators, CFSAN head Michael Landa says.

EU Health Ministers Want Changes to COVID-19 Vaccine Contracts Amid Oversupply Concerns

EU member states are calling for a formal approach to making vaccine procurement agreements more flexible, saying that any further delay will “undermine the trust of society in vaccination and vaccines.”

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS139493

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel